Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.
Rezdiffra's Triumph | Madrigal's NASH treatment shows impressive early adoption, with prescription rates soaring to 47% and potential peak sales of $6-7.4 billion |
Financial Projections | Analyst targets range from $155 to $530 per share, reflecting diverse views on Madrigal's prospects, with Q4 2024 revenue estimates around $91 million |
Market Access Evolution | Explore how improvements in reimbursement processes are accelerating Rezdiffra's market penetration, with paid drug access increasing to 58% |
Growth Horizons | Delve into Madrigal's potential for expanding Rezdiffra's indications and capturing a larger share of the growing NASH treatment market |
Metrics to compare | MDGL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMDGLPeersSector | |
---|---|---|---|---|
P/E Ratio | −15.5x | 0.0x | −0.5x | |
PEG Ratio | 1.62 | 0.00 | 0.00 | |
Price/Book | 9.6x | 1.2x | 2.6x | |
Price / LTM Sales | 40.1x | 11.2x | 2.9x | |
Upside (Analyst Target) | 23.9% | 374.8% | 60.5% | |
Fair Value Upside | Unlock | 16.1% | 8.5% | Unlock |